Cardinal Health-Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Cardinal Health reported $55.26 billion in revenue for the quarter ended December 2024, a year-over-year decline of 3.8%, with an EPS of$ 1.93 compared to $1.82 a year ago, indicating a positive surprise of +10.29% over the consensus estimate [1] Revenue Performance - Revenue from Pharmaceutical and Specialty Solutions was$ 50.85 billion, slightly above the average estimate of $50.76 billion, but down 4.4% year-over-year [4] - Revenue from Other segments reached$ 1.28 billion, exceeding the average estimate of $1.23 billion [4] - Revenue from Medical Products and Distribution was$ 3.15 billion, slightly below the average estimate of $3.18 billion, reflecting a year-over-year change of -0.4% [4] Segment Profitability - Segment profit for Pharmaceutical and Specialty Solutions was$ 531 million, surpassing the average estimate of $496.49 million [4] - Segment profit for Other segments was$ 118 million, exceeding the average estimate of $110.67 million [4] - Segment profit for Global Medical Products and Distribution was$ 18 million, below the average estimate of $25.77 million [4] Stock Performance - Cardinal Health's shares have returned +8% over the past month, outperforming the Zacks S&P 500 composite's +1.2% change, with a Zacks Rank 2 (Buy) indicating potential for further outperformance [3]